Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Creative Planning

Creative Planning increased its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 31.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 44,914 shares of the biopharmaceutical company's stock after purchasing an additional 10,668 shares during the quarter. Creative Planning's holdings in Insmed were worth $3,279,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. EntryPoint Capital LLC purchased a new stake in shares of Insmed during the first quarter worth $33,000. Fidelis Capital Partners LLC purchased a new stake in Insmed during the 1st quarter valued at about $34,000. GAMMA Investing LLC raised its holdings in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 224 shares during the last quarter. First Horizon Advisors Inc. lifted its stake in Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 287 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock worth $55,000 after purchasing an additional 627 shares in the last quarter.

Wall Street Analysts Forecast Growth

INSM has been the subject of several recent research reports. StockNews.com cut Insmed from a "hold" rating to a "sell" rating in a report on Friday, August 9th. UBS Group raised their target price on Insmed from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Bank of America boosted their price target on shares of Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a research report on Wednesday, October 9th. HC Wainwright restated a "buy" rating and set a $90.00 price objective on shares of Insmed in a research report on Thursday, August 29th. Finally, TD Cowen boosted their target price on shares of Insmed from $75.00 to $98.00 and gave the company a "buy" rating in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $82.73.

Insider Buying and Selling

In related news, insider Martina M.D. Flammer sold 13,436 shares of the company's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares in the company, valued at approximately $7,951,559.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares of the company's stock, valued at $7,157,150. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares of the company's stock, valued at $7,951,559.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock valued at $5,765,446 in the last three months. 4.60% of the stock is owned by corporate insiders.

Insmed Stock Down 1.0 %

Shares of INSM traded down $0.75 during mid-day trading on Friday, hitting $70.96. 674,453 shares of the company's stock were exchanged, compared to its average volume of 1,187,836. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The company has a market cap of $12.19 billion, a price-to-earnings ratio of -13.17 and a beta of 1.11. The stock's 50-day moving average is $73.83 and its 200-day moving average is $60.03. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.72). The business had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. During the same period in the previous year, the company earned ($1.78) earnings per share. The firm's revenue for the quarter was up 17.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Insmed Incorporated will post -5.41 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.